Parallel Aspects of the Microenvironment in Cancer and Autoimmune Disease

Mediators of Inflammation

Volumn 2016, Issue , 2016, Pages

  Rahat, Michal A ^a   Shakya, Jivan ^a  

^a CARMEL MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHEMOKINE; REACTIVE OXYGEN METABOLITE; CYTOKINE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER TISSUE; CHRONIC INFLAMMATION; HUMAN; HYPOXIA; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; MACROPHAGE; MONOCYTE; NEUTROPHIL; OXYGEN TENSION; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; IMMUNOLOGY; METABOLISM; NEOPLASM;

AUTOIMMUNE DISEASES; CHEMOKINES; CYTOKINES; NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 84960969043     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2016/4375120     Document Type: Review

References (181)

1. V. Bronte, "Tumor cells hijack macrophages via lactic acid, " Immunology and Cell Biology, vol. 92, pp. 647-649, 2014.
2. H. F. Dvorak, "Tumors: wounds that do not heal-redux, " Cancer Immunology Research, vol. 3, no. 1, pp. 1-11, 2015.
3. A. B. Glick, A. Wodzinski, P. Fu, A. D. Levine, andD. N. Wald, "Impairment of regulatory T-Cell function in autoimmune thyroid disease, " Thyroid, vol. 23, no. 7, pp. 871-878, 2013.
4. B. Bolon, "Cellular and molecular mechanisms of autoimmune disease, " Toxicologic Pathology, vol. 40, no. 2, pp. 216-229, 2012.
5. G. Helmlinger, F. Yuan, M. Dellian, and R. K. Jain, "Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation, " Nature Medicine, vol. 3, no. 2, pp. 177-182, 1997.
6. M. Molls, H. J. Feldmann, and J. Fuller, "Oxygenation of locally advanced recurrent rectal cancer, soft tissue sarcoma and breast cancer, " Advances in Experimental Medicine and Biology, vol. 345, pp. 459-463, 1994.
7. A. L. Davies, R. A. Desai, P. S. Bloomfield et al., "Neurological deficits caused by tissue hypoxia in neuroinflammatory disease, " Annals of Neurology, vol. 74, no. 6, pp. 815-825, 2013.
8. K. J. Kim, I. W. Baek, C. H. Yoon, W. U. Kim, and C. S. Cho, "Anemic hypoxia is associatedwith increased pulmonary artery systolic pressure in patients with systemic lupus erythematosus, " Arthritis Care & Research, 2015.
9. A. Carreau, B. E. Hafny-Rahbi, A. Matejuk, C. Grillon, and C. Kieda, "Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia, " Journal of Cellular and Molecular Medicine, vol. 15, no. 6, pp. 1239-1253, 2011.
10. M. Biniecka, E. Fox, W. Gao et al., "Hypoxia induces mitochondrial mutagenesis and dysfunction in inflammatory arthritis, " Arthritis & Rheumatism, vol. 63, no. 8, pp. 2172-2182, 2011.
11. A. Kennedy, C. T. Ng, M. Biniecka et al., "Angiogenesis and blood vessel stability in inflammatory arthritis, " Arthritis & Rheumatism, vol. 62, no. 3, pp. 711-721, 2010.
12. B. Muz, M. N. Khan, S. Kiriakidis, andE. M. Paleolog, "Hypoxia. The role of hypoxia and HIF-dependent signalling events in rheumatoid arthritis, " Arthritis Research and Therapy, vol. 11, article 201, 2009.
13. A. Del Prete, P. Allavena, G. Santoro, R. Fumarulo, M. M. Corsi, and A. Mantovani, "Molecular pathways in cancerrelated inflammation, " BiochemiaMedica, vol. 21, no. 3, pp. 264-275, 2011.
14. M. Ehlers andM. Schott, "Hashimoto's thyroiditis and papillary thyroid cancer: are they immunologically linked?" Trends in Endocrinology & Metabolism, vol. 25, no. 12, pp. 656-664, 2014.
15. F. Balkwill, K. A. Charles, and A. Mantovani, "Smoldering and polarized inflammation in the initiation and promotion of malignant disease, " Cancer Cell, vol. 7, no. 3, pp. 211-217, 2005.
16. A. L. Franks and J. E. Slansky, "Multiple associations between a broad spectrumof autoimmune diseases, chronic inflammatory diseases and cancer, " Anticancer Research, vol. 32, no. 4, pp. 1119-1136, 2012.
17. F. Colotta, P. Allavena, A. Sica, C. Garlanda, and A. Mantovani, "Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability, " Carcinogenesis, vol. 30, no. 7, pp. 1073-1081, 2009.
18. S. Bernatsky, J. F. Boivin, L. Joseph et al., "An international cohort study of cancer in systemic lupus erythematosus, " Arthritis & Rheumatism, vol. 52, no. 5, pp. 1481-1490, 2005.
19. E. Tatsis, E. Reinhold-Keller, K. Steindorf, A. C. Feller, and W. L. Gross, "Wegener's granulomatosis associated with renal cell carcinoma, " Arthritis and Rheumatism, vol. 42, no. 4, pp. 751-756, 1999.
20. A. A. Shah and A. Rosen, "Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications, " Current Opinion in Rheumatology, vol. 23, no. 6, pp. 530-535, 2011.
21. C. G. Joseph, E. Darrah, A. A. Shah et al., "Association of the autoimmune disease scleroderma with an immunologic response to cancer, " Science, vol. 343, no. 6167, pp. 152-157, 2014.
22. K. Movahedi, D. Laoui, C. Gysemans et al., "Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes, " Cancer Research, vol. 70, no. 14, pp. 5728-5739, 2010.
23. S. Cameron, M. Gieselmann, M. Blaschke, G. Ramadori, and L. Füzesi, "Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST), " International Journal ofClinical and Experimental Pathology, vol. 7, no. 7, pp. 3563-3579, 2014.
24. W. Kazmierczak, A. Lazar, R. Tomaszewska et al., "Analysis of the intensity of immune cell infiltration and immunoreactivity of RCAS1 in diffuse large B-cell lymphoma of the palatine tonsil and its microenvironment, " Cell and Tissue Research, vol. 361, no. 3, pp. 823-831, 2015.
25. F. Dai, L. Liu, G. Che et al., "The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer, " BMC Cancer, vol. 10, article 220, 2010.
26. J. Ma, L. Liu, G. Che, N. Yu, F. Dai, and Z. You, "TheM1 formof tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time, " BMC Cancer, vol. 10, article 112, 2010.
27. S. Shimura, G. Yang, S. Ebara, T. M. Wheeler, A. Frolov, and T. C. Thompson, "Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression, " Cancer Research, vol. 60, no. 20, pp. 5857-5861, 2000.
28. H. Kurahara, H. Shinchi, Y. Mataki et al., "Significance of M2-polarized tumor-associated macrophage in pancreatic cancer, " Journal of Surgical Research, vol. 167, no. 2, pp. e211-e219, 2011.
29. Q. Zhou, R.-Q. Peng, X.-J. Wu et al., "The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer, " Journal of Translational Medicine, vol. 8, article 13, 2010.
30. E. I. Deryugina, E. Zajac, A. Juncker-Jensen, T. A. Kupriyanova, L. Welter, and J. P. Quigley, "Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment, " Neoplasia, vol. 16, no. 10, pp. 771-788, 2014.
31. E. B. Eruslanov, P. S. Bhojnagarwala, J. G. Quatromoni et al., "Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer, " The Journal of Clinical Investigation, vol. 124, no. 12, pp. 5466-5480, 2014.
32. H. K. Jensen, F. Donskov, N. Marcussen, M. Nordsmark, F. Lundbeck, and H. von der Maase, "Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma, " Journal of Clinical Oncology, vol. 27, no. 28, pp. 4709-4717, 2009.
33. Z. G. Fridlender, J. Sun, S. Kim et al., "Polarization of tumorassociated neutrophil phenotype by TGF-: 'N1' versus 'N2' TAN, " Cancer Cell, vol. 16, no. 3, pp. 183-194, 2009.
34. U. Sack, P. Stieh, and G. Geiler, "Distribution of macrophages in rheumatoid synovial membrane and its association with basic activity, " Rheumatology International, vol. 13, no. 5, pp. 181-186, 1994.
35. J. D. Ma, J. J. Zhou, D. H. Zheng et al., "Serum matrix metalloproteinase-3 as a noninvasive biomarker of histological synovitis for diagnosis of rheumatoid arthritis, " Mediators of Inflammation, vol. 2014, Article ID 179284, 10 pages, 2014.
36. J. A. Gómez-Puerta, R. Celis, M. V. Hernández et al., "Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide/protein antibody-positive and-negative rheumatoid arthritis patients, " Arthritis Research & Therapy, vol. 15, no. 6, article R182, 2013.
37. L. G. M. van Baarsen, M. C. Lebre, D. van der Coelen et al., "Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?" Arthritis Research & Therapy, vol. 16, no. 4, article 426, 2014.
38. D. Y. S. Vogel, E. J. F. Vereyken, J. E. Glim et al., "Macrophages in inflammatorymultiple sclerosis lesions have an intermediate activation status, " Journal of Neuroinflammation, vol. 10, article 35, 2013.
39. L. Schiffer, R. Bethunaickan, M. Ramanujam et al., "Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis, " Journal of Immunology, vol. 180, no. 3, pp. 1938-1947, 2008.
40. R. Bethunaickan, C. C. Berthier, M. Ramanujam et al., "A unique hybrid renal mononuclear phagocyte activation phenotype inmurine systemic lupus erythematosus nephritis, " Journal of Immunology, vol. 186, no. 8, pp. 4994-5003, 2011.
41. V. Juniantito, T. Izawa, T. Yuasa et al., "Immunophenotypical characterization of macrophages in rat bleomycin-induced scleroderma, " Veterinary Pathology, vol. 50, no. 1, pp. 76-85, 2013.
42. X. Yang, J. Yang, X. Xing, L. Wan, and M. Li, "Increased frequency ofTh17 cells in systemic sclerosis is related to disease activity and collagen overproduction, " Arthritis Research and Therapy, vol. 16, article R4, 2014.
43. D. W. Wojkowska, P. Szpakowski, D. Ksiazek-Winiarek, M. Leszczynski, and A. Glabinski, "Interactions between neutrophils, Th17 cells, and chemokines during the initiation of experimental model of multiple sclerosis, " Mediators of Inflammation, vol. 2014, Article ID 590409, 8 pages, 2014.
44. S. P. Zehntner, C. Brickman, L. Bourbonnière, L. Remington, M. Caruso, and T. Owens, "Neutrophils that infiltrate the central nervous system regulate T cell responses, " The Journal of Immunology, vol. 174, no. 8, pp. 5124-5131, 2005.
45. S. B. Simmons, D. Liggitt, and J. M. Goverman, "Cytokineregulated neutrophil recruitment is required for brain but not spinal cord inflammation during experimental autoimmune encephalomyelitis, " Journal of Immunology, vol. 193, no. 2, pp. 555-563, 2014.
46. A. Midgley and M. W. Beresford, "Increased expression of low density granulocytes in juvenile-onset systemic lupus erythematosus patients correlates with disease activity, " Lupus, 2015.
47. I. Papandreou, A. Powell, A. L. Lim, and N. Denko, "Cellular reaction to hypoxia: sensing and responding to an adverse environment, " Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 569, no. 1-2, pp. 87-100, 2005.
48. M. A. Rahat, H. Bitterman, and N. Lahat, "Molecular mechanisms regulatingmacrophage response to hypoxia, " Frontiers in Immunology, vol. 2, article 45, 2011.
49. S. B. Coffelt, R. Hughes, and C. E. Lewis, "Tumor-associated macrophages: effectors of angiogenesis and tumor progression, " Biochimica et Biophysica Acta, vol. 1796, no. 1, pp. 11-18, 2009.
50. S. R. Walmsley, E. R. Chilvers, and M. K. B. Whyte, "Hypoxia. Hypoxia, hypoxia inducible factor and myeloid cell function, " Arthritis Research & Therapy, vol. 11, no. 2, article 219, 2009.
51. C. Strehl, M. Fangradt, U. Fearon, T. Gaber, F. Buttgereit, andD. J. Veale, "Hypoxia: how does themonocyte-macrophage system respond to changes in oxygen availability?" Journal of Leukocyte Biology, vol. 95, no. 2, pp. 233-241, 2014.
52. C. R. Justus, E. J. Sanderlin, and L. V. Yang, "Molecular connections between cancer cell metabolism and the tumor microenvironment, " International Journal ofMolecular Sciences, vol. 16, no. 5, pp. 11055-11086, 2015.
53. C. Behn, O. F. Araneda, A. J. Llanos, G. Celedón, and G. González, "Hypoxia-related lipid peroxidation: evidences, implications and approaches, " Respiratory Physiology and Neurobiology, vol. 158, no. 2-3, pp. 143-150, 2007.
54. T. Minko, Y. Wang, and V. Pozharov, "Remediation of cellular hypoxic damage by pharmacological agents, " Current Pharmaceutical Design, vol. 11, no. 24, pp. 3185-3199, 2005.
55. H. K. Eltzschig, "Targeting hypoxia-induced inflammation, " Anesthesiology, vol. 114, no. 2, pp. 239-242, 2011.
56. M. Crowther, N. J. Brown, E. T. Bishop, and C. E. Lewis, "Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors, " Journal of Leukocyte Biology, vol. 70, no. 4, pp. 478-490, 2001.
57. M. V. Blagosklonny, "Antiangiogenic therapy and tumor progression, " Cancer Cell, vol. 5, no. 1, pp. 13-17, 2004.
58. L. I. Cárdenas-Navia, D. Yu, R. D. Braun, D. M. Brizel, T. W. Secomb, and M. W. Dewhirst, "Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing, " Cancer Research, vol. 64, no. 17, pp. 6010-6017, 2004.
59. O. R. Colegio, N.-Q. Chu, A. L. Szabo et al., "Functional polarization of tumour-associated macrophages by tumourderived lactic acid, " Nature, vol. 513, no. 7519, pp. 559-563, 2014.
60. P. Bergsten, J. Westerlund, P. Liss, and P.-O. Carlsson, "Primary in vivo oscillations of metabolism in the pancreas, " Diabetes, vol. 51, no. 3, pp. 699-703, 2002.
61. J. Lengfeld, T. Cutforth, and D. Agalliu, "The role of angiogenesis in the pathology of multiple sclerosis, " Vascular Cell, vol. 6, article 23, 2014.
62. A. M. Amorini, V. Nociti, A. Petzold et al., "Serum lactate as a novel potential biomarker in multiple sclerosis, " Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1842, no. 7, pp. 1137-1143, 2014.
63. J. Liu, X. Wang, X. Yang, Q. Yan, S. Wang, and W. Han, "Investigating the role of angiogenesis in systemic lupus erythematosus, " Lupus, vol. 24, no. 6, pp. 621-627, 2015.
64. V. Liakouli, P. Cipriani, A. Marrelli, S. Alvaro, P. Ruscitti, and R. Giacomelli, "Angiogenic cytokines and growth factors in systemic sclerosis, " Autoimmunity Reviews, vol. 10, no. 10, pp. 590-594, 2011.
65. H. M. Farouk, S. H. Hamza, S. A. El Bakry et al., "Dysregulation of angiogenic homeostasis in systemic sclerosis, " International Journal of Rheumatic Diseases, vol. 16, no. 4, pp. 448-454, 2013.
66. R. D. Stout and J. Suttles, "Functional plasticity ofmacrophages: reversible adaptation to changing microenvironments, " Journal of Leukocyte Biology, vol. 76, no. 3, pp. 509-513, 2004.
67. R. D. Stout, S. K. Watkins, and J. Suttles, "Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages, " Journal of Leukocyte Biology, vol. 86, no. 5, pp. 1105-1109, 2009.
68. D. M. Mosser, "The many faces of macrophage activation, " Journal of Leukocyte Biology, vol. 73, no. 2, pp. 209-212, 2003.
69. F. O. Martinez, A. Sica, A. Mantovani, and M. Locati, "Macrophage activation and polarization, " Frontiers in Bioscience, vol. 13, no. 2, pp. 453-461, 2008.
70. C. Murdoch, M. Muthana, S. B. Coffelt, and C. E. Lewis, "The role of myeloid cells in the promotion of tumour angiogenesis, " Nature Reviews Cancer, vol. 8, no. 8, pp. 618-631, 2008.
71. S. Gordon and F. O. Martinez, "Alternative activation of macrophages: mechanism and functions, " Immunity, vol. 32, no. 5, pp. 593-604, 2010.
72. D. M. Mosser and J. P. Edwards, "Exploring the full spectrum of macrophage activation, " Nature Reviews Immunology, vol. 8, no. 12, pp. 958-969, 2008.
73. B.-Z. Qian and J. W. Pollard, "Macrophage diversity enhances tumor progression and metastasis, " Cell, vol. 141, no. 1, pp. 39-51, 2010.
74. F. O. Martinez and S. Gordon, "The M1 and M2 paradigm of macrophage activation: time for reassessment, " F1000Prime Reports, vol. 6, article 13, 2014.
75. D. I. Gabrilovich and S. Nagaraj, "Myeloid-derived suppressor cells as regulators of the immune system, " Nature Reviews Immunology, vol. 9, no. 3, pp. 162-174, 2009.
76. S. Ostrand-Rosenberg and P. Sinha, "Myeloid-derived suppressor cells: linking inflammation and cancer, " Journal of Immunology, vol. 182, no. 8, pp. 4499-4506, 2009.
77. V. Bronte, "Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions, " European Journal of Immunology, vol. 39, no. 10, pp. 2670-2672, 2009.
78. V. Bronte and P. Zanovello, "Regulation of immune responses by L-arginine metabolism, " Nature Reviews Immunology, vol. 5, no. 8, pp. 641-654, 2005.
79. G. P. Dunn, L. J. Old, and R. D. Schreiber, "The three Es of cancer immunoediting, " Annual Review of Immunology, vol. 22, pp. 329-360, 2004.
80. R. D. Schreiber, L. J. Old, and M. J. Smyth, "Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, " Science, vol. 331, no. 6024, pp. 1565-1570, 2011.
81. B.-Z. Qian, J. Li, H. Zhang et al., "CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis, " Nature, vol. 475, no. 7355, pp. 222-225, 2011.
82. R. N. Hanna, C. Cekic, D. Sag et al., "Patrolling monocytes control tumor metastasis to the lung, " Science, vol. 350, no. 6263, pp. 985-990, 2015.
83. K. L. Wong, W. H. Yeap, J. J. Y. Tai, S. M. Ong, T. M. Dang, and S. C. Wong, "The three human monocyte subsets: implications for health and disease, " Immunologic Research, vol. 53, no. 1-3, pp. 41-57, 2012.
84. M. De Palma, C. Murdoch, M. A. Venneri, L. Naldini, and C. E. Lewis, "Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications, " Trends in Immunology, vol. 28, no. 12, pp. 519-524, 2007.
85. M. Egeblad, A. J. Ewald, H. A. Askautrud et al., "Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy, " Disease Models & Mechanisms, vol. 1, no. 2-3, pp. 155-167, 2008.
86. C. E. Lewis and J. W. Pollard, "Distinct role of macrophages in different tumor microenvironments, " Cancer Research, vol. 66, no. 2, pp. 605-612, 2006.
87. M. A. Venneri, M. De Palma, M. Ponzoni et al., "Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer, " Blood, vol. 109, no. 12, pp. 5276-5285, 2007.
88. J. Wyckoff, W. Wang, E. Y. Lin et al., "A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors, " Cancer Research, vol. 64, no. 19, pp. 7022-7029, 2004.
89. L. Hernandez, T. Smirnova, D. Kedrin et al., "The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin beta1 and CXCL12, " Cancer Research, vol. 69, no. 7, pp. 3221-3227, 2009.
90. A. Sica, P. Allavena, and A. Mantovani, "Cancer related inflammation: the macrophage connection, " Cancer Letters, vol. 267, no. 2, pp. 204-215, 2008.
91. S. Daniliuc, H. Bitterman, M. A. Rahat, A. Kinarty, D. Rosenzweig, and L. Nitza, "Hypoxia inactivates inducible nitric oxide synthase in mouse macrophages by disrupting its interaction with -actinin 4, " The Journal of Immunology, vol. 171, no. 6, pp. 3225-3232, 2003.
92. N. Lahat, M. A. Rahat, A. Kinarty, L. Weiss-Cerem, S. Pinchevski, and H. Bitterman, "Hypoxia enhances lysosomal TNF- degradation in mouse peritoneal macrophages, " The American Journal of Physiology-Cell Physiology, vol. 295, no. 1, pp. C2-C12, 2008.
93. M. A. Rahat, B. Marom, H. Bitterman, L. Weiss-Cerem, A. Kinarty, and N. Lahat, "Hypoxia reduces the output of matrix metalloproteinase-9 (MMP-9) in monocytes by inhibiting its secretion and elevating membranal association, " Journal of Leukocyte Biology, vol. 79, no. 4, pp. 706-718, 2006.
94. A. Sica, P. Larghi, A. Mancino et al., "Macrophage polarization in tumour progression, " Seminars in Cancer Biology, vol. 18, no. 5, pp. 349-355, 2008.
95. C. Maueröder, L. E. Munoz, R. A. Chaurio, M. Herrmann, G. Schett, and C. Berens, "Tumor immunotherapy: lessons from autoimmunity, " Frontiers in Immunology, vol. 5, article 212, 2014.
96. M. Walter, E. Simanovich, V. Brod, N. Lahat, H. Bitterman, and M. A. Rahat, "An epitope-specific novel anti-EMMPRIN polyclonal antibody inhibits tumor progression, " OncoImmunology, 2015.
97. M. J. Gough, N. Killeen, and A. D. Weinberg, "Targeting macrophages in the tumour environment to enhance the efficacy of OX40 therapy, " Immunology, vol. 136, no. 4, pp. 437-447, 2012.
98. Z. G. Fridlender, A. Jassar, I. Mishalian et al., "Using macrophage activation to augment immunotherapy of established tumours, " British Journal of Cancer, vol. 108, no. 6, pp. 1288-1297, 2013.
99. T. Ueno, M. Toi, H. Saji et al., "Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer, " Clinical Cancer Research, vol. 6, no. 8, pp. 3282-3289, 2000.
100. C. Chavey, F. Bibeau, S. Gourgou-Bourgade et al., "Oestrogen receptor negative breast cancers exhibit high cytokine content, " Breast Cancer Research, vol. 9, no. 1, article R15, 2007.
101. R. Kokebie, R. Aggarwal, S. Lidder et al., "The role of synovial fluid markers of catabolism and anabolism in osteoarthritis, rheumatoid arthritis and asymptomatic organ donors, " Arthritis Research &Therapy, vol. 13, no. 2, article R50, 2011.
102. L. J. Edwards, B. Sharrack, A. Ismail, H. Tumani, and C. S. Constantinescu, "Central inflammation versus peripheral regulation in multiple sclerosis, " Journal of Neurology, vol. 258, no. 8, pp. 1518-1527, 2011.
103. V. Ramirez-Ramirez, M. A. Macias-Islas, G. G. Ortiz et al., "Efficacy of fish oil on serumof TNF , IL-1, and IL-6 oxidative stress markers inmultiple sclerosis treated with interferon beta-1b, " OxidativeMedicine and Cellular Longevity, vol. 2013, Article ID 709493, 8 pages, 2013.
104. S. Garcia-Rodriguez, J.-L. Callejas-Rubio, N. Ortego-Centeno et al., "Altered AKT1 and MAPK1 gene expression on peripheral blood mononuclear cells and correlation with T-helpertranscription factors in Systemic Lupus Erythematosus patients, " Mediators of Inflammation, vol. 2012, Article ID 495934, 14 pages, 2012.
105. V. Umare, V. Pradhan, M. Nadkar et al., "Effect of proinflammatory cytokines (IL-6, TNF-, and IL-1) on clinical manifestations in indian SLE patients, " Mediators of Inflammation, vol. 2014, Article ID 385297, 8 pages, 2014.
106. L. Petrovic-Rackov and N. Pejnovic, "Clinical significance of IL-18, IL-15, IL-12 and TNF- measurement in rheumatoid arthritis, " Clinical Rheumatology, vol. 25, no. 4, pp. 448-452, 2006.
107. A. Mouzaki, M. Rodi, N. Dimisianos et al., "Immune parameters that distinguish multiple sclerosis patients from patientswith other neurological disorders at presentation, " PLoS ONE, vol. 10, no. 8, Article ID e0135434, 2015.
108. C. Malmeström, B. A. Andersson, S. Haghighi, andJ. Lycke, "IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles, " Journal of Neuroimmunology, vol. 175, no. 1-2, pp. 176-182, 2006.
109. A. Zickert, P. Amoudruz, Y. Sundström, J. Rönnelid, V. Malmstr öm, and I. Gunnarsson, "IL-17 and IL-23 in lupus nephritis-association to histopathology and response to treatment, " BMC Immunology, vol. 16, article 7, 2015.
110. E. Robak, P. Smolewski, A. Wozniacka, A. Sysa-Jedrzejowska, H. Stepién, and T. Robak, "Relationship between peripheral blood dendritic cells and cytokines involved in the pathogenesis of systemic lupus erythematosus, " European Cytokine Network, vol. 15, no. 3, pp. 222-230, 2004.
111. Z. Yin, J. Huang, W. He et al., "Serum level of eight cytokines in Han Chinese patients with systemic lupus erythematosus using multiplex fluorescent microsphere method, " Central European Journal of Immunology, vol. 39, no. 2, pp. 228-235, 2014.
112. S. Shahrara, Q. Huang, A. M. Mandelin II, andR. M. Pope, "TH-17 cells in rheumatoid arthritis, " Arthritis Research & Therapy, vol. 10, no. 4, article R93, 2008.
113. S. Desruisseau, J. Palmari, C. Giusti, S. Romain, P.-M. Martin, and Y. Berthois, "Determination of TGFI protein level in human primary breast cancers and its relationship with survival, " British Journal of Cancer, vol. 94, no. 2, pp. 239-246, 2006.
114. A. E. Koch, S. L. Kunkel, L. A. Harlow et al., "Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis, " Journal of Clinical Investigation, vol. 90, no. 3, pp. 772-779, 1992.
115. J. W. Bauer, E. C. Baechler, M. Petri et al., "Elevated serumlevels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus, " PLoS Medicine, vol. 3, no. 12, article e491, 2006.
116. H. Bartosik-Psujek and Z. Stelmasiak, "Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients, " Journal of Neural Transmission, vol. 112, no. 6, pp. 797-803, 2005.
117. E. Maae, D. A. Olsen, K. D. Steffensen et al., "Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer, " Breast Cancer Research and Treatment, vol. 133, no. 1, pp. 257-265, 2012.
118. H. R. Kim, K. W. Kim, B. M. Kim, M. L. Cho, and S. H. Lee, "The effect of vascular endothelial growth factor on osteoclastogenesis in rheumatoid arthritis, " PLoS ONE, vol. 10, no. 4, Article ID e0124909, 2015.
119. M. J. Bottomley, N. J. A. Webb, C. J. Watson et al., "Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is coexpressedwithVEGF in synovial fluid, " Clinical&Experimental Immunology, vol. 119, no. 1, pp. 182-188, 2000.
120. E. Tham, A. W. Gielen, M. Khademi, C. Martin, and F. Piehl, "Decreased expression of VEGF-A in rat experimental autoimmune encephalomyelitis and in cerebrospinal fluid mononuclear cells from patients with multiple sclerosis, " Scandinavian Journal of Immunology, vol. 64, no. 6, pp. 609-622, 2006.
121. E. Robak, A. Sysa-Jedrzejewska, and T. Robak, "Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus, " Mediators of Inflammation, vol. 12, no. 5, pp. 293-298, 2003.
122. B. Bielekova, M. Komori, Q. Xu, D. S. Reich, and T. Wu, "Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation, " PLoS ONE, vol. 7, no. 11, Article ID e48370, 2012.
123. B. S. Palacios, L. Estrada-Capetillo, E. Izquierdo et al., "Macrophages fromthe synoviumof active rheumatoid arthritis exhibit an activin a-dependent pro-inflammatory profile, " The Journal of Pathology, vol. 235, no. 3, pp. 515-526, 2015.
124. L. T. Donlin, A. Jayatilleke, E. G. Giannopoulou, G. D. Kalliolias, and L. B. Ivashkiv, "Modulation of TNF-induced macrophage polarization by synovial fibroblasts, " Journal of Immunology, vol. 193, no. 5, pp. 2373-2383, 2014.
125. L. A. N. Peferoen, D. Y. S. Vogel, K. Ummenthum et al., "Activation status of human microglia is dependent on lesion formation stage and remyelination in multiple sclerosis, " Journal of Neuropathology and Experimental Neurology, vol. 74, no. 1, pp. 48-63, 2014.
126. L. Ding, H. Gu, X. Gao, S. Xiong, and B. Zheng, "Aurora kinase a regulates M1 macrophage polarization and plays a role in experimental autoimmune encephalomyelitis, " Inflammation, vol. 38, no. 2, pp. 800-811, 2015.
127. W. Zhang, W. Xu, and S. Xiong, "Blockade of Notch1 signaling alleviatesmurine lupus via bluntingmacrophage activation and M2b polarization, " The Journal of Immunology, vol. 184, no. 11, pp. 6465-6478, 2010.
128. J. Orme and C. Mohan, "Macrophage subpopulations in systemic lupus erythematosus, " Discovery Medicine, vol. 13, no. 69, pp. 151-158, 2012.
129. M. Manetti, "Deciphering the alternatively activated (M2) phenotype of macrophages in scleroderma, " Experimental Dermatology, vol. 24, no. 8, pp. 576-578, 2015.
130. A. Kato, M. Yutani, M. Terao et al., "Oligosaccharide modification by N-acetylglucosaminyltransferase-V in macrophages are involved in pathogenesis of bleomycin-induced scleroderma, " Experimental Dermatology, vol. 24, no. 8, pp. 585-590, 2015.
131. C. C. Bain and A. M. Mowat, "The monocyte-macrophage axis in the intestine, " Cellular Immunology, vol. 291, no. 1-2, pp. 41-48, 2014.
132. K. Molawi, Y. Wolf, P. K. Kandalla et al., "Progressive replacement of embryo-derived cardiac macrophages with age, " The Journal of Experimental Medicine, vol. 211, no. 11, pp. 2151-2158, 2014.
133. A. Shemer and S. Jung, "Differential roles of resident microglia and infiltrating monocytes in murine CNS autoimmunity, " Seminars in Immunopathology, vol. 37, no. 6, pp. 613-623, 2015.
134. B. A. Blok, R. J. Arts, R. vanCrevel, C. S. Benn, andM. G. Netea, "Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines, " Journal of Leukocyte Biology, vol. 98, no. 3, pp. 347-356, 2015.
135. F. Shojaei, M. Singh, J. D. Thompson, and N. Ferrara, "Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 7, pp. 2640-2645, 2008.
136. H. H. Yan, M. Pickup, Y. Pang et al., "Gr-1+CD11b+myeloid cells tip the balance ofimmune protection to tumor promotion in the premetastatic lung, " Cancer Research, vol. 70, no. 15, pp. 6139-6149, 2010.
137. M. Kowanetz, X. Wu, J. Lee et al., "Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes, " Proceedings of the NationalAcademy of Sciences of the United States of America, vol. 107, no. 50, pp. 21248-21255, 2010.
138. Z. Granot, E. Henke, E. A. Comen, T. A. King, L. Norton, and R. Benezra, "Tumor entrained neutrophils inhibit seeding in the premetastatic lung, " Cancer Cell, vol. 20, no. 3, pp. 300-314, 2011.
139. S. Punt, J. M. Langenhoff, H. Putter, G. J. Fleuren, A. Gorter, and E. S. Jordanova, "The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review, " OncoImmunology, vol. 4, no. 2, Article ID e984547, 2015.
140. S. Punt, G. J. Fleuren, E. Kritikou et al., "Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer, " OncoImmunology, vol. 4, Article ID e984539, 2015.
141. L. Benevides, D. M. da Fonseca, P. B. Donate et al., "IL17 promotes mammary tumor progression by changing the behavior of tumor cells and eliciting tumorigenic neutrophils recruitment, " Cancer Research, vol. 75, no. 18, pp. 3788-3799, 2015.
142. S. B. Coffelt, K. Kersten, C. W. Doornebal et al., "IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis, " Nature, vol. 522, no. 7556, pp. 345-348, 2015.
143. R. Cascão, H. S. Rosário, M. M. Souto-Carneiro, and J. E. Fonseca, "Neutrophils in rheumatoid arthritis: more than simple final effectors, " Autoimmunity Reviews, vol. 9, no. 8, pp. 531-535, 2010.
144. J. Talbot, F. J. Bianchini, D. C. Nascimento et al., "CCR2 Expression in neutrophils plays a critical role in their migration into the joints in rheumatoid arthritis, " Arthritis & Rheumatology, vol. 67, no. 7, pp. 1751-1759, 2015.
145. M. Katayama, K. Ohmura, N. Yukawa et al., "Neutrophils are essential as a source of IL-17 in the effector phase of arthritis, " PLoS ONE, vol. 8, no. 5, Article ID e62231, 2013.
146. M. Naegele, K. Tillack, S. Reinhardt, S. Schippling, R. Martin, andM. Sospedra, "Neutrophils in multiple sclerosis are characterized by a primed phenotype, " Journal of Neuroimmunology, vol. 242, no. 1-2, pp. 60-71, 2012.
147. M. Battaglia, "Neutrophils and type 1 autoimmune diabetes, " Current Opinion in Hematology, vol. 21, no. 1, pp. 8-15, 2014.
148. R. Bayley, K. A. Kite, H. M. McGettricket al., "The autoimmuneassociated genetic variant PTPN22 R620W enhances neutrophil activation and function in patients with rheumatoid arthritis and healthy individuals, " Annals of the Rheumatic Diseases, vol. 74, pp. 1588-1595, 2015.
149. B. A. Kidd, P. P. Ho, O. Sharpe et al., "Epitope spreading to citrullinated antigens in mousemodels of autoimmune arthritis and demyelination, " Arthritis Research & Therapy, vol. 10, no. 5, article R119, 2008.
150. E. R. Vossenaar, S. Nijenhuis, M. M. A. Helsen et al., "Citrullination of synovial proteins in murine models of rheumatoid arthritis, " Arthritis&Rheumatism, vol. 48, no. 9, pp. 2489-2500, 2003.
151. B. Pinegin, N. Vorobjeva, and V. Pinegin, "Neutrophil extracellular traps and their role in the development of chronic inflammation and autoimmunity, " Autoimmunity Reviews, vol. 14, no. 7, pp. 633-640, 2015.
152. M. F. Denny, S. Yalavarthi, W. Zhao et al., "A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs, " The Journal of Immunology, vol. 184, pp. 3284-3297, 2010.
153. H.-F. Pan, X.-H. Fang, G.-C. Wu et al., "Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus and lupus nephritis, " Inflammation, vol. 31, no. 4, pp. 260-265, 2008.
154. E. Pieterse and J. van der Vlag, "Breaking immunological tolerance in systemic lupus erythematosus, " Frontiers in Immunology, vol. 5, article 164, 2014.
155. M. T. Silva and M. Correia-Neves, "Neutrophils and macrophages: the main partners of phagocyte cell systems, " Frontiers in Immunology, vol. 3, article 174, 2012.
156. C. A. Dumitru, H. Gholaman, S. Trellakis et al., "Tumorderived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation, " International Journal of Cancer, vol. 129, no. 4, pp. 859-869, 2011.
157. L. L. Santos, H. Fan, P. Hall et al., "Macrophage migration inhibitory factor regulates neutrophil chemotactic responses in inflammatory arthritis in mice, " Arthritis & Rheumatism, vol. 63, no. 4, pp. 960-970, 2011.
158. A. A. Filardy, D. R. Pires, M. P. Nunes et al., "Proinflammatory clearance of apoptotic neutrophils induces an IL-12(low)IL-10(high) regulatory phenotype in macrophages, " Journal of Immunology, vol. 185, no. 4, pp. 2044-2050, 2010.
159. G. Zizzo and P. L. Cohen, "IL-17 stimulates differentiation of human anti-inflammatory macrophages and phagocytosis of apoptotic neutrophils in response to IL-10 and glucocorticoids, " The Journal of Immunology, vol. 190, no. 10, pp. 5237-5246, 2013.
160. A. N. Burska, L. Hunt, M. Boissinot et al., "Autoantibodies to posttranslational modifications in rheumatoid arthritis, " Mediators of Inflammation, vol. 2014, Article ID 492873, 19 pages, 2014.
161. R. Holmdahl, V. Malmström, and H. Burkhardt, "Autoimmune priming, tissue attack and chronic inflammation-the three stages of rheumatoid arthritis, " European Journal of Immunology, vol. 44, no. 6, pp. 1593-1599, 2014.
162. S. Yung and T. M. Chan, "Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis: getting to know the unknown, " Clinical and Developmental Immunology, vol. 2012, Article ID 139365, 13 pages, 2012.
163. E. M. Tan, "Antinuclear antibodies defining autoimmunity pathways, " Arthritis Research & Therapy, vol. 16, no. 1, article 104, 2014.
164. J. X. Shi, J. J. Qin, H. Ye, P. Wang, K. J. Wang, and J. Y. Zhang, "Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis, " Expert Review of Molecular Diagnostics, vol. 15, no. 6, pp. 829-852, 2015.
165. S. Qi, M. Huang, H. Teng et al., "Autoantibodies to chromogranin A are potential diagnostic biomarkers for non-small cell lung cancer, " Tumor Biology, vol. 36, no. 12, pp. 9979-9985, 2015.
166. E. I. Goufman, V. N. Iakovlev, N. B. Tikhonova, and A. E. Lokshin, "Quantification of autoantibodies to plasminogen in plasma of patients with cancer, " Cancer Biomarkers, vol. 15, no. 3, pp. 281-287, 2015.
167. R. Bei, L. Masuelli, C. Palumbo, M. Modesti, andA. Modesti, "A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: inflammation in their induction and impact on tumor growth, " Cancer Letters, vol. 281, no. 1, pp. 8-23, 2009.
168. M. E. Mohammed and K. Abdelhafiz, "Autoantibodies in the sera of breast cancer patients: antinuclear and anti-double stranded DNA antibodies as example, " Journal of Cancer Research andTherapeutics, vol. 11, no. 2, pp. 341-344, 2015.
169. G. Assmann, K. Shihadeh, V. Poeschel et al., "Prevalence of anticitrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study, " PLoS ONE, vol. 9, no. 2, Article ID e88177, 2014.
170. M. Muthana, A. Giannoudis, S. D. Scott et al., "Use of macrophages to target therapeutic adenovirus to human prostate tumors, " Cancer Research, vol. 71, no. 5, pp. 1805-1815, 2011.
171. C. Twyman-Saint Victor, A. J. Rech, A. Maity et al., "Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer, " Nature, vol. 520, no. 7547, pp. 373-377, 2015.
172. X. Li, W. Yao, Y. Yuan et al., "Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma, " Gut, 2015.
173. S. Shahrara, A. E. I. Proudfoot, C. C. Park et al., "Inhibition of monocyte chemoattractant protein-1 ameliorates rat adjuvantinduced arthritis, "TheJournal of Immunology, vol. 180, no. 5, pp. 3447-3456, 2008.
174. S. A. Chalmers, V. Chitu, L. C. Herlitz, R. Sahu, E. R. Stanley, and C. Putterman, "Macrophage depletion ameliorates nephritis induced by pathogenic antibodies, " Journal of Autoimmunity, vol. 57, pp. 42-52, 2015.
175. A. Inoue, H. Hasegawa, M. Kohno et al., "Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice, " Arthritis & Rheumatism, vol. 52, no. 5, pp. 1522-1533, 2005.
176. E. M. Bekes, B. Schweighofer, T. A. Kupriyanova et al., "Tumorrecruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency ofmalignant cell intravasation, "TheAmerican Journal of Pathology, vol. 179, no. 3, pp. 1455-1470, 2011.
177. H. Verbeke, S. Struyf, N. Berghmans et al., "Isotypicneutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth andmetastasis, " Cancer Letters, vol. 302, no. 1, pp. 54-62, 2011.
178. X. G. Wang, Q. Meng, F. M. Qi, andQ. F. Yang, "Blocking TGFbeta inhibits breast cancer cell invasiveness via ERK/S100A4 signal, " European Review for Medical and Pharmacological Sciences, vol. 18, pp. 3844-3853, 2014.
179. K. Garrison, T. Hahn, W.-C. Lee, L. E. Ling, A. D. Weinberg, and E. T. Akporiaye, "The small molecule TGF- signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress establishedmammary tumors and reduce spontaneous metastasis, " Cancer Immunology, Immunotherapy, vol. 61, no. 4, pp. 511-521, 2012.
180. M. Uhl, S. Aulwurm, J. Wischhusen et al., "SD-208, a novel transforming growth factor receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo, " Cancer Research, vol. 64, no. 21, pp. 7954-7961, 2004.
181. B. Zhang, S. K. Halder, S. Zhang, and P. K. Datta, "Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer, " Cancer Letters, vol. 277, no. 1, pp. 114-120, 2009.